Rochester, NY (PRWEB) May 14, 2004 -
Â Dr. Michael Connolly, CEO and founder of Integrated Nano-Technologies (INT), will serve on a panel with representatives from leading defense contractors and the US military discussing ÂNanotechnology and Defense,Â the role of nanotechnology in military applications, at the third annual NanoBusiness conference, May 17-19, 2004 at the Marriott Financial Center Hotel in New York City. The NanoBusiness conference showcases advances in nanotechnology and brings together investors, engineers, and business leaders to discuss imminent product developments and long range plans.
INTÂs core technology, integrates DNA and microelectronics to develop advanced, nano-scale, bio-electronic innovations that solve some of the greatest challenges in biosecurity, clinical diagnostics and other fields. INTÂs technology platform, called BioDetect, is fully automated, portable, non-PCR nucleic acid identification system that can accurately detect the presence of biological agents such as anthrax, plague, and smallpox in as little as 20 minutes. Defense agencies are anxious to deploy detection and identification systems that operate at the level of sensitivity and accuracy that the BioDetect platform is capable of.
About INTÂs Technology
Integrated Nano-TechnologiesÂ core technology is a unique integration of molecular biology, chemistry and microelectronics which facilitates the development of technically advanced detection systems and other devices. Biological agent identification is based on the ability of DNA probes on a microchip to attract and bind to specific sequences in the DNA of a target organism. DNA is extracted from a sample and passed over a sensor, where it attaches to the organism-specific probes. The attached strands are metalized through a chemical process, producing a strong electrical signal for computer analysis.
The BioDetect platform consists of an electronic analyzer and single-use, disposable test cards. Unlike other detection systems, BioDetectÂ technology does not depend on polymerase chain reaction (PCR), and consequently does not share PCRÂs problems with speed, stability and sensitivity.
About Integrated Nano-Technologies, LLC
Rochester, NY-based Integrated Nano-Technologies, LLC is a leading innovator in highly accurate, sensitive, rapid, portable, electronic, biological agent identification technology. Built around the BioDetectÂ Platform, INTÂs devices are highly portable and use disposable test cards to test field samples for numerous biological agents, including anthrax, in as little as 20 minutes. Future developments of the platform will enable the medical community to identify specific illness causing pathogens in patients without sending samples out to laboratories; facilitating faster and more accurate treatment regimens. For more information about Integrated Nano-Technologies, call 585-334-0170 or visit their Web site at http://www.integratednano.com.
About NanoBusiness 2004
New technologies. New materials. New applications. Designed specifically with real world business solutions in mind. That's the business of nanotechnology. Only one event attracts all the key stakeholders in this industry. NanoBusiness 2004. Now in its third year, this event has become the "must attend" conference for the scientific and engineering communities, business leaders and investors. Last year over 500 were in attendance! Produced by the NanoBusiness Alliance, this is the only nano event designed for the industry, by the industry. http://www.nanobusiness2004.com
This press release contains forward-looking statements that are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.